Cancer was cured over 30 years ago in a mouse. Anti-CD47 therapy will almost certainly fail in human trials.
I agree with Lipomas, in 1997 James Watson predicted that Judah Folkmann's endostatin and angiostatin angiogenesis inhibitor compounds would cure ALL cancer within 2 years. Shares of Entremed Inc. shot up above $100 for a brief period after he was quoted in the NY times. Today, shares are at $2.
I knew some of Weismann's postdocs when I was at the farm. This is pure hype. Same old story, works in a mouse, total failure in humans. Immense clonal diversity of cancers will make this disease incurable during our lifetime. You can add months or even a year or two with targeted therapies, but for the big cancers (breast, colon, pancreas, lung) you can never hit all the genetically distinct clones.
I would short shares of Weismann's biotech company once they shoot up after a promising mouse study. Furthermore, it's a great strategy to short any publicly-traded biotech company with a promising cancer therapy.